Condition: Glioblastoma · Brain Cancer · Glioblastoma Multiforme · Sponsor: Baptist Health South Florida
The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to take the study drug ruxolitinib in addition to the standard of care temozolomide and radiation therapy and the other half will be assigned to the standard of care temozolomide and radiation therapy only. This assignment will be randomized in a 1-to-1 ratio, like the flip of a coin.
This description comes directly from the study's public registry record.
Manmeet Ahluwalia, M.D., MBA · (786) 596-2000 · ManmeetA@baptisthealth.net
MCI Multisite Research Program · MCIMultisiteResearch@baptisthealth.net
Always discuss trial participation with your own doctor first.
| Miami Cancer Institute at Baptist Health, Inc. | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06991101